Upadacitinib vs Adalimumab in PsA using RAPID3 Save
Dr. Catherine Sims discusses abstract 0192 presented at ACR22 Convergence. 0192: Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.